JAK2V617F-positive essential thrombocythemia and multiple myeloma with IGH/CCND1 gene translocation coexist, but originate from separate clones

Acta Haematologica

Volumn 120, Issue 3, 2009, Pages 177-181

  Kuroda, Junya ^a   Matsumoto, Yosuke ^a   Tanaka, Ruriko ^b   Kurita, Kayoko ^a   Kobayashi, Tsutomu ^a   Shimizu, Daisuke ^a   Kimura, Shinya ^b   Ashihara, Eishi ^b   Horiike, Shigeo ^a   Shimazaki, Chihiro ^a   Taniwaki, Masafumi ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Double color fluorescence in situ hybridization; Essential thrombocythemia; IGH CCND1; JAK2V617F; Multiple myeloma

Indexed keywords

CYCLIN D1; IMMUNOGLOBULIN HEAVY CHAIN; JANUS KINASE; SYNDECAN 1;

ADULT; ARTICLE; CANCER GROWTH; CASE REPORT; CELL DIFFERENTIATION; CELL PROLIFERATION; COMORBIDITY; CYTOTOXICITY; DISEASE EXACERBATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE TRANSLOCATION; HEMATOPOIETIC CELL; HUMAN; MULTIPLE MYELOMA; PRIORITY JOURNAL; THROMBOCYTHEMIA;

AGED; AMINO ACID SUBSTITUTION; CYCLIN D1; FEMALE; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; JANUS KINASE 2; LEUKOCYTES; MULTIPLE MYELOMA; MUTATION, MISSENSE; SYNDECAN-1; THROMBOCYTOPENIA; TRANSLOCATION, GENETIC;

EID: 58149157480     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000187645     Document Type: Article

References (23)

1. Selroos O, van Assendelft A: Thrombocythaemia and multiple myeloma. A report on two cases. Acta Med Scand 1977;201:243-247.
2. Prósper F, Borbolla JR, Rifón J, Cuesta B, Fernández J, Pinacho A, Rocha E: Coexistence of essential thrombocythemia and multiple myeloma. Ann Hematol 1992;65:103-105.
3. Kelsey PR, Patel K: Essential thrombocythaemia followed by multiple myeloma in the same patient. Clin Lab Haematol 1995;17:349-351.
4. Arlen PM, Goldkland GA: Multiple myeloma after treatment of essential thrombocythemia. South Med J 1995;88:79-81.
5. Cobo F, Cervantes F, Martinez C, Salgado C, Blade J, Montserrat E, Rozman C: Multiple myeloma following essential thrombocythemia. Leuk Lymphoma 1995;20:177-179.
6. Candoni A, Tiribelli M, Fanin R: Plasma cell leukemia occurring in a patient with thrombocythemia treated with hydroxyurea and busulphan. Leuk Lymphoma 2004;45:821-824.
7. Majhail NS, Lichtin AE: Rare coexistence of multiple myeloma with essential thrombocythemia: report of two cases. Haematologica 2003;88:e34-e35.
8. Hoffman R, Prchal JT, Samuelson S, Ciurea SO, Rondelli D: Philadelphia chromosome-negative myeloproliferative disorders: biology and treatment. Biol Blood Marrow Transplant 2007;13:64-72.
9. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC: A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-1790.
10. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D'Andrea A, Fröhling S, Döhner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-397.
11. Tefferi A: Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era. Hematology Am Soc Hematol Educ Program 2006:240-245.
12. Kralovics R, Teo SS, Li S, Theocharides A, Buser AS, Tichelli A, Skoda RC: Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood 2006;108:1377-1380.
13. Jamieson CH, Gotlib J, Durocher JA, Chao MP, Mariappan MR, Lay M, Jones C, Zehnder JL, Lilleberg SL, Weissman IL: The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci USA 2006;103:6224-6229.
14. Fiorini A, Farina G, Reddiconto G, Palladino M, Rossi E, Za T, Laurenti L, Giammarco S, Chiusolo P, Leone G, Sica S: Screening of JAK2 V617F mutation in multiple myeloma. Leukemia 2006;20:1912-1913.
15. González D, van der Burg M, García-Sanz R, Fenton JA, Langerak AW, González M, van Dongen JJ, San Miguel JF, Morgan GJ: Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood 2007;110:3112-3121.
16. Gabrea A, Leif Bergsagel P, Michael Kuehl W: Distinguishing primary and secondary translocations in multiple myeloma. DNA Repair (Amst) 2006;5:1225-1233.
17. Tanaka R, Kuroda J, Stevenson W, Ashihara E, Ishikawa T, Taki T, Kobayashi Y, Kamitsuji Y, Kawata E, Takeuchi M, Murotani Y, Yokota A, Hirai M, Majima S, Taniwaki M, Maekawa T, Kimura S: Fully automated and super-rapid system for the detection of JAK2V617F mutation. Leuk Res 2008;32:1462-1467.
18. Nishida K, Tamura A, Nakazawa N, Ueda Y, Abe T, Matsuda F, Kashima K, Taniwaki M: The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. Blood 1997;90:526-534.
19. International Myeloma Working Group: Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749-757.
20. Lasho TL, Mesa R, Gilliland DG, Tefferi A: Mutation studies in CD3+, CD19+ and CD34+ cell fractions in myeloproliferative disorders with homozygous JAK2(V617F) in granulocytes. Br J Haematol 2005;130:797-799.
21. Hussein K, Bock O, Seegers A, Flasshove M, Henneke F, Buesche G, Kreipe HH: Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation. Blood 2007;109:4106-4107.
22. Inami M, Inokuchi K, Okabe M, Kosaka F, Mitamura Y, Yamaguchi H, Dan K: Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia. Leukemia 2007;21:1103-1104.
23. Curtin NJ, Campbell PJ, Green AR: The Philadelphia translocation and pre-existing myeloproliferative disorders. Br J Haematol 2005;128:734-736.